Clinical Cases with Deep Venous Thrombosis - The position of Apixaban Stavros KAKKOS, MD, MSc, PhD, RVT
|
|
- Milo Patrick
- 5 years ago
- Views:
Transcription
1 Clinical Cases with Deep Venous Thrombosis - The position of Apixaban Stavros KAKKOS, MD, MSc, PhD, RVT Department of Vascular Surgery. University Hospital of Patras Chairman: Ioannis Tsolakis
2 DISCLAIMER The opinions expressed in this presentation belong to the presenter and do not necessarily reflect the views of the company. For all medicinal products mentioned, please refer to the approved Summaries of Product Characteristics.
3 Deep Vein Thrombosis Venous Gangrene
4 Risk of recurrent VTE Initial 1 (0 έως ~7 days) Stages of VTE treatment Long-term (~7 days to ~3 months Extended/secondary prevention (after ~3 months) Parenteral* (VKA) or other factors Treatment Secondary prevention Time from initiation of treatment Initiation of treatment and secondary prevention End of teatment * Heparin, low molecular weight heparin (LMWH), fondaparinux. Includes LMWH and NOACs 1. Kearon C et al. Chest. 2012;141(2 Suppl):e419s-e494s. 2. Kearon C. J Thromb Haemost. 2012;10:
5 Thrombosis Bleeding Disadvantages of VKAs Narrow therapeutic window thrombosis bleeding Difficulty maintaining INR within this window Numerous food & drug interactions Require frequent monitoring of INR and narrow therapeutic window dose adjustments Slow onset and end of action Increased risk of bleeding Dose
6 Targets of DOACs Xll Xl lx TF VIIIa Va X VII Direct inhibitors of Xa Rivaroxaban, Apixaban II Direct inhibitors of thrombin Dabigatran I Fibrin clot Adopted from Ansell J. J Thromb Haemost. 2007;5(suppl 1): Turpie AGG. Arterioscler Thromb Vasc Biol. 2007;27:
7 Apixaban: a direct oral anticoagulant (DOAC) Apixaban (Eliquis/Pfizer και Bristol-Myers Squibb)
8 O Apixaban O N NH 2 N O N N O No prodrug Bioavailability: ~50% T max : 3 4 hours ~87% binding to plasma proteins T 1/2 : ~12 hours Apixaban SmPC Pinto et al. J Med Chem. 2007;50(22):
9 Apixaban is equally effective with eno/warfarin RR 0.84 (95% confidence interval [CI], 0.60 to 1.18; P<0.001 for noninferiority). AMPLIFY, NEJM 2013
10 Practice change with DOACs No INR monitoring Reduced drug and no food interactions No ΗΙΤ Monotherapy (only apixaban and rivaroxaban) Forget bridge therapy Pay attention to renal function
11
12 Practice change with DOACs I forgot to tell you something No INR monitoring very important! Reduced drug and no food interactions No ΗΙΤ Monotherapy (only apixaban and rivaroxaban) Forget bridge therapy Pay attention to renal function
13
14 Practice change with DOACs Treatment: reduced frequency of major bleeding 1.08% 1.73% Kakkos, Kirkilesis, Tsolakis. EJVES 2014
15 Event rate (% /year) Event rate (% /year) Event rate (%/year) Event rate (% /year) Event rate (% /year) AMPLIFY Primary Safety Outcome: Major Bleeding* Major Bleeding* 0.6 n= n= Major + CRNM Bleeding 4.3 n=115 Apixaban 9.7 n=261 Enoxaparin/Warfarin P<0.001 RR=0.44 (95% CI ) CRNM Bleeding 3.8 n=103 Apixaban 8.0 n=215 Enoxaparin/Warfarin P not reported RR=0.48 (95% CI ) 0.0 Apixaban P<0.001 RR=0.31 (95% CI ) Enoxaparin/warfarin blood, occurred into a critical site, or contributed to death. CI, confidence interval; CRNM, clinically relevant nonmajor; RR, relative risk Minor Bleeding n=313 Apixaban 18.8 n=505 Enoxaparin/Warfarin P not reported RR= (95% CI ) All Bleeding n=402 Apixaban 25.1 n=676 Enoxaparin/Warfarin P not reported RR= (95% CI ) Clinically relevant nonmajor bleeding was defined as overt bleeding but associated with medical intervention, contact with a physician, interruption of the study drug, or discomfort or impairment in carrying out activities of daily life. Secondary safety outcome was the composite of major or clinically relevant nonmajor bleeding. * Bleeding was defined as major if it was overt and associated with a decrease in the hemoglobin level of 2 g/dl, required the transfusion of 2 units of 1 Apixaban SmPC Created from Agnelli G et al. N Engl J Med. 2013;369:
16 AMPLIFY EXT, NEJM 2013
17 Practice change with DOACs Treatment: reduced frequency of deaths due to major bleeding 0.09% 0.18% Kakkos, Kirkilesis, Tsolakis. EJVES 2014
18 Practice change with DOACs Treatment: reduced frequency of clinically significant non-major bleeding 6.6% 8.5% Kakkos, Kirkilesis, Tsolakis. EJVES 2014
19 Practice change with DOACs Secondary prevention: reduced frequency of VTE 1.3% 7.2% Kakkos, Kirkilesis, Tsolakis. EJVES 2014
20 Practice change with DOACs Secondary prevention: reduced frequency of fatal PE Kakkos, Kirkilesis, Tsolakis. EJVES 2014
21 Practice change with DOACs Secondary prevention: reduced frequency of all cause death 0.41% 0.86% Kakkos, Kirkilesis, Tsolakis. EJVES 2014
22 Antidote for Apixaban Adnexanet alpha On May 4 th 2018
23 Presentations of clinical cases
24 Case No 1 57 year old Caucasian female with a past medical history of hypertension on treatment and surgery for breast cancer stage IIa some 10 years ago, disease free on her last follow-up, presented to the emergency room of an outside hospital with a two day history of massive swelling of the right leg.
25 Case No 1 Duplex scanning revealed extensive DVT Admitted to hospital Renal function: WNL Started on a LMWH Tumor recurrence was ruled out Discharged on LMWH after 3 days PET scan: WNL/no uptake
26 Case No 1 After 10 days on LMWH, our patient developed a large skin necrosis at the injection site in her abdomen
27 Case No 1 Referred by the Dermatology service asking for advice regarding anticoagulation options in this case of apparent heparin-induced skin necrosis Hematomas
28 Case No 1 Cessation of LMWH Was it necessary in the first instance? Well-informed patient, requested a DOAC Fear of bleeding! Apixaban was deemed appropriate.
29 Case No 1 Apixaban SPC Start treatment with apixaban 10mg BID for 7 days and then switch to 5mg BID
30 Case No 1 Apixaban SPC Start treatment with apixaban 10mg BID for 7 days and then switch to 5mg BID HOWEVER applicable only for the initial stage of treatment! Therefore in this case: start on apixaban 5mg BID
31 Case No 2 35 year old healthy motorbike driver had a low-speed accident and sustained a fibula fracture and also a grade 1 knee sprain on his L leg Cast and LMWH
32 Case No 2 Presented to the ER some 15 days later complaining of new-onset calf pain. Duplex: extensive calf vein thrombosis PLT count: WNL Thromboprophylaxis cannot be 100% effective!
33 Case No 2 Treatment options 1. Increase the dose of the LMWH: patient denied to continue on a failed treatment
34 Case No 2 Treatment options 1. Increase the dose of the LMWH: patient denied to continue on a failed treatment 2. Observation with repeat 6 weeks: not indicated due to the presence of Sx.
35 Case No 2 Treatment options 1. Increase the dose of the LMWH: patient denied to continue on a failed treatment 2. Observation with repeat 6 weeks: not indicated due to the presence of Sx. 3. Switch to apixaban: 5mg BID
36 Treatment options 1. Increase the dose of the LMWH: patient denied to continue on a failed treatment 2. Observation with repeat 6 weeks: not indicated due to the presence of Sx. 3. Switch to apixaban: 5mg BID 4. Switch to apixaban: 10 mg BID for 1/52 then 5mg BID Case No 2
37 Case No 2 Duration of treatment Fear of bleeding 6 weeks? 6 months? Indefinite?
38 VTE recurrence Frequency after Tx cessation Unprovoked Other risk factors* Baglin, Lancet 2003 Recent surgery * Except pregnancy and surgery
39 Duration of anticoagulation Tx: recurrence 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% patients with a first episode of provoked DVT or PE Three months 6-12 months RR % CI 0.74 to 1.32 No recurrence Recurrence Pinede, Circulation, 2001 Agnelli, Ann Intern Med, 2003 Agnelli, NEJM, 2003 Campbell, BMJ, 2007 ICS, 2003
40 Duration of anticoagulation Tx: major bleeding 10% 9% 8% 7% 6% 5% 4% 3% 2% 1% 0% 3 months 6-12 months RR % CI 1.16 to 5.83 Absence of major bleeding Major bleeding Pinede, Circulation, 2001 Agnelli, Ann Intern Med, 2003 Agnelli, NEJM, 2003 Campbell, BMJ, 2007 ICS, 2003
41 Case No 2 The correct answer (not listed) is three months of apixaban monotherapy
42 Case No 3 86 year old female presents with acute onset L leg swelling and pain diagnosed as DVT on Duplex scanning Otherwise healthy, underweight (45Kg) Labs: creatinine 2mg%
43 Case No 3 86 year old female presents with acute onset L leg swelling and pain diagnosed as DVT on Duplex scanning Otherwise healthy, underweight (45Kg) Labs: creatinine 2mg% e-gfr: 14.3 ml/min
44 Case No 3 CAUTION ALL DOACS REQUIRE GFR CALCULATION CONTRAINDICATED IN SEVERE RENAL FAILURE TO AVOID BLEEDING AND PRESERVE THEIR REPUTATION!
45 Case No 4 54 year old male with a PMH of HT & NIDDM had an episode of unprovoked DVT of his R leg some 5 years ago, treated with LMWH - acenocoumarol for 6 months. Recurrence of DVT with nearly fatal PE a month after he stopped anticoagulation.
46 VTE recurrence Frequency after Tx cessation Unprovoked VTE n=1,626 Provoked VTE Prandoni, Haematologica 2007
47 Case No 4 Recurrence was treated with thrombolysis, LMWH - acenocoumarol. No stop date. Regular INR checks. Labile INR readings, often below 2. Increasing anxiety about potential of another recurrence. Psychiatry visit.
48 Case No 4 A year after recurrent DVT had occurred he presented to my outpatient clinic with painless swelling of his right leg started 6/12 ago. Gradual deterioration worse in PM, subsides after bed rest. Duplex: no recurrence.
49 Post thrombotic syndrome Risk factors Early symptoms Iliofemoral DVT Recurrence of DVT Elderly Obesity Females Subtherapeutic INR Kahn, Ann Intern Med Van Dongen, J Thromb Haemost 2005
50 Case No 4 Reflux in the popliteal vein on additional testing What to do next?
51 Case No 4 Treat PTS with a class 2 elastic stocking. Optimum anticoagulation in patients with established PTS?
52 Case No 4 Apixaban will provide a stable anticoagulation level and was actually proposed to the patient. Patient is now very happy with the proposal. He understood well the need for prolonged treatment.
53 Case No 4 Any consideration missing??
54 Case No 4 Any consideration missing?? Dose!
55 Case No 4 5 mg BID? 2.5 mg BID?
56 AMPLIFY EXT, NEJM 2013
57 AMPLIFY EXT, NEJM 2013
58 Case No 5 45 year old female with an unremarkable PMH sustained a minor skiing accident with a left ankle sprain. Family history included father with unprovoked DVT at the age of 60. Cast and thromboprophylaxis.
59 Case No 5 Returned after 9 days with pain and swelling of the left leg, requiring cast removal, examination confirming edema with tenderness on OE. Duplex: CFV
60 Interpretation? Case No 5
61 VTE recurrence Frequency after Tx cessation Unprovoked Other risk factors* Baglin, Lancet 2003 Recent surgery * Except pregnancy and surgery
62 OPTIMAL DURATION STRATEGY Acute PE or DVT Provoked Gray Zone Unprovoked 3-6 Months Rx Individualize Rx Consider Lifelong Rx Consider past/family VTE history, gender, recanalization of leg veins on U/S, hypercoagulability, patient preference Courtesy of Samuel Goldhaber Circulation 2011
63 Case No 5 A clear case for apixaban monotherapy 10mg BID for 7 days 5mg BID for 3 months Dose reduction after 6 months: 2.5mg BID
64 Case No 6 29 year old female with longstanding varicose veins. Hereditary, related also to occupation (hair dresser). Conservatively managed (elastic compression stockings, venoactive drugs)
65 Case No 6 Superficial Vein Thrombosis (SVT) Kakkos et al, Thrombosis Research 2010
66 Clinical manifestations of SVT Rubor Pain Local edema Palpable firm thrombi Mostly a clinical diagnosis
67 Superficial Vein Thrombosis ` Duplex: Extensive thrombosis of the left great saphenous vein, measuring 30 cm in length GSV incompetence Incompressible great saphenous on US probe compression
68 Exclusion of deep-vein thrombosis in patients with SVT is necessary (level of evidence high)
69 Case No 6 SVT extending through perforators into gastrocnemius (deep) veins
70 Superficial Vein Thrombosis is not a Benign Disease A significant proportion (10-20%) of patients has already extension of thrombosis into the deep venous system, fact that necessitates a duplex scan to be performed to R/O DVT. A significant proportion of patients (10% in POST) will develop extension or recurrence during the first three months.
71 From January 1992 to January 1996, 263 patients were identified with superficial venous thrombosis isolated to the superficial veins with no evidence of deep venous involvement by duplex ultrasound examination. Thirty (11%) patients had documented progression to deep venous involvement within 2-10 days. J Vasc Surg 1996;24:745-9.)
72 Patterns of extension into the deep veins From the greater saphenous vein in the thigh into the common femoral vein (SFJ, n=21, 70%), with 18 of these extensions noted to be non occlusive and 12 having a free-floating component. From the above-knee saphenous vein through thigh perforators to occlude the femoral vein in the thigh (n=3). Below-knee saphenous disease into the popliteal vein (?SPJ, n=3) Below-knee thrombi into the tibioperoneal veins through calf perforators (n=3). Chengelis, J Vasc Surg 1996
73 Superficial Vein Thrombosis is not a Benign Disease Three-Month Incidence of Venous Thromboembolic Events in Isolated SVT Thromboembolic Event (n 586) Incidence [95% CI], n (%)* Any 58 (10.2 [ ]) Symptomatic 46 (8.3 [ ]) PE or DVT 18 (3.3 [ ]) DVT 15 (2.8 [ ]) Proximal 7 Distal 8 PE 3 (0.5 [0 1.2]) SVT Recurrence 10 (1.9 [ ]) Extension 18 (3.3 [ ]) Asymptomatic 12 (2.1 [ ]) 8.3% symptomatic thromboembolic 3 months *Percentages are probabilities computed by using survival curve analysis. Assessed by compression ultrasonography 8 14 days after presentation.
74 Case No 6 Because of extension into the deep veins, apixaban was prescribed for three months. Varicose vein surgery afterwards. Without recurrence three years later. No need for extended anticoagulation.
75 Three-year cumulative rates of deep-vte recurrence (DVT or pulmonary embolism [PE]) in patients with a first isolated SVT or a first isolated proximal DVT Galanaud JTH 2017
76 Case No 7 74 year old male with a PMH of HT and DLP presented to the ER department with a five day history of right leg pain and calf tenderness. Two-point Duplex WNL, d-dimers not measured. Returned two days later because of clear deterioration of his symptoms.
77 Case No 7 What went wrong?
78 Case No 7 Repeat Duplex scan revealed extensive calf vein thrombosis
79 Case No 7 Treatment options Observation with repeat scanning? Prophylactic anticoagulation? Therapeutic anticoagulation? Type? Duration?
80 Case No 7 ACCP 2016
81 Case No 7 ACCP 2016
82 Need for long-term anticoagulant treatment after a 1 st episode of symptomatic calf-vein thrombosis Three-month follow-up OPEN LABEL RCT P< % * proven by venography Lagerstedt, 1985, Lancet
83 Need for long-term anticoagulant treatment after a 1 st episode of symptomatic calf-vein thrombosis One-year follow-up P< % 32% * proven by venography Lagerstedt, 1985, Lancet
84 Need for long-term anticoagulant treatment after a 1 st episode of symptomatic calf-vein thrombosis Lagerstedt, 1985, Lancet
85 Case No 7 ACCP 2016
86 Case No 7 Apixaban 10mg BID for 7 days and then switch to 5mg BID for three months
87 Conclusions Apixaban has a wide range of indications in patients with DVT of the leg during the acute phase of the disease and in the long term. Extremely useful in extended treatment of DVT for the purposes of safe and also effective secondary prevention using a halved dose.
88 Ευχαριστώ! Danke! Thank you! Grazie! תודה Tack! Dank je! Hvala vam!
With All the New Drugs, This is How I Treat Acute DVT and Superficial Phlebitis
BRIGHAM AND WOMEN S HOSPITAL With All the New Drugs, This is How I Treat Acute DVT and Superficial Phlebitis Gregory Piazza, MD, MS Division of Cardiovascular Medicine Brigham and Women s Hospital April
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationDirect Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
More informationUPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS
UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following
More informationRapid Fire-Top Articles You Need to Know
Rapid Fire-Top Articles You Need to Know TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE- SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Financial Disclosures-NONE
More informationA Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism
Cardiol Ther (2018) 7:1 13 https://doi.org/10.1007/s40119-018-0107-0 REVIEW A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism Andrew
More informationUnderstanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR
Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism Rajat Deo, MD, MTR Director of Translational Research in Cardiac Arrhythmias Division of Cardiovascular Medicine
More informationCURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM. Gordon Lowe Professor of Vascular Medicine University of Glasgow
CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM Gordon Lowe Professor of Vascular Medicine University of Glasgow VENOUS THROMBOEMBOLISM Common cause of death and disability 50% hospital-acquired
More informationThe clinical relevance of AMPLIFY programme
Venice October 16th 2015 The clinical relevance of AMPLIFY programme Francesco Dentali Department of Clinical Medicine Insubria University Varese Disclosures Bayer Bristol-Myers Squibb/Pfizer Boehringer
More informationThe Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for
The Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for Anticoagulation Services Sanford USD Medical Center Sioux Falls,
More informationFocus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018
Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018 NO DISCLOSURE Pulmonary Embolism Venous thromboembolism (VT) is the third most common cause of cardiovascular
More informationDisclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None
Disclosures DVT: Diagnosis and Treatment None Susanna Shin, MD, FACS Assistant Professor University of Washington Acute Venous Thromboembolism (VTE) Deep Venous Thrombosis (DVT) Pulmonary Embolism (PE)
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationMabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationDuration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium
Duration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium Disclosures Honoraria and research support: Daiichi-Sankyo, Boehringer Ingelheim,
More informationVenous Thromboembolic Disease Update
Canadian Society of Internal Medicine Annual Meeting Calgary, Alberta, October 2014 Venous Thromboembolic Disease Update Benjamin Bell, MD FRCPC James Douketis, MD FRCPC On Behalf of Thrombosis Canada
More informationDr. Riaz JanMohamed Consultant Haematologist The Hillingdon Hospital Foundation Trust
MANAGEMENT OF PATIENTS WITH DEEP VEIN THROMBOSIS (DVT) IN THE COMMUNITY SETTING & ANTICOAGULATION CLINICS THE PAST, PRESENT AND THE FUTURE Dr. Riaz JanMohamed Consultant Haematologist The Hillingdon Hospital
More informationVenous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community
Venous Thrombosis Venous Thrombosis It occurs mainly in the deep veins of the leg (deep vein thrombosis, DVT), from which parts of the clot frequently embolize to the lungs (pulmonary embolism, PE). Fewer
More informationCHAPTER 2 VENOUS THROMBOEMBOLISM
CHAPTER 2 VENOUS THROMBOEMBOLISM Objectives Venous Thromboembolism (VTE) Prevalence Patho-physiology Risk Factors Diagnosis Pulmonary Embolism (PE) Management of DVT/PE Prevention VTE Patho-physiology
More informationNew Oral Anticoagulant Drugs in the Prevention of DVT
New Oral Anticoagulant Drugs in the Prevention of DVT Targets for Anticoagulants ORAL DIRECT VKAs inhibit the hepatic synthesis of several coagulation factors Rivaroxaban Apixaban Edoxaban Betrixaban X
More informationExpanding the treatment options of Superficial vein thrombosis with Rivaroxaban
Expanding the treatment options of Superficial vein thrombosis with Rivaroxaban Athanasios D. Giannoukas MD, MSc(Lond.), PhD(Lond.), FEBVS Professor of Vascular Surgery Faculty of Medicine, School of Health
More informationUpdates in Management of Venous Thromboembolic Disease
Updates in Management of Venous Thromboembolic Disease November 7 th 2018 UHN Emergency Conference Susan Jenkins RN(EC) NP-Adult Thrombosis and Hemostasis Program University Health Network Disclosures
More informationSpontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren
Spontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren Paul Kyrle Allgemeines Krankenhaus Wien Disclosures relevant for this presentation Consultancies, member of advisory boards, speaker
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC 1 st workshop: update to VTE guidelines in 2016 2 nd workshop: VTE controversies + new horizons André Roussin MD, FRCP, CSPQ CHUM
More informationThe latest on the diagnosis and treatment of venous thromboembolism
The latest on the diagnosis and treatment of venous thromboembolism Vicky Tagalakis MD FRCP Division of General Internal Medicine Jewish General Hospital McGill University Disclosures Advisory board Pfizer
More informationDiagnosis and Management of Venous Thromboembolism
Diagnosis and Management of Venous Thromboembolism Muhammad Sajid Pervaiz Consultant Haematologist Chairman VTE committee Pennine Acute Hospitals NHS trust TOPICS 1-Introduction (Seriousness of problem)
More informationDuration of Therapy for Venous Thromboembolism
Duration of Therapy for Venous Thromboembolism Michael B Streiff, MD FACP Associate Professor of Medicine and Pathology Medical Director, Johns Hopkins Anticoagulation Service Chairman, VTE Guideline Committee
More informationDVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center
DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients David Liff MD Oklahoma Heart Institute Vascular Center Overview Pathophysiology of DVT Epidemiology and risk factors for DVT in the
More informationKeynote lecture: Oral anticoagulation and DVT
Keynote lecture: Oral anticoagulation and DVT What is the evidence? Is there a need to anticoagulate every lower leg DVT? Disclosure Speaker name:...sebastian Schellong... I have the following potential
More informationDVT - initial management NSCCG
Background information Information resources for patients and carers Updates to this care map Synonyms Below knee DVT and bleeding risks Patient with confirmed DVT Scan confirms superficial thrombophlebitis
More informationCurrent issues in the management of Superficial Vein Thrombosis - SVT
Current issues in the management of Superficial Vein Thrombosis - SVT Athanasios D. Giannoukas MD, MSc(Lond.), PhD(Lond.), FEBVS Professor of Vascular Surgery Faculty of Medicine, School of Health Sciences,
More informationAcute Versus Chronic DVT Imaging in the Vascular Lab Heather Gornik, MD, RVT, RPVI
Acute Versus Chronic DVT Imaging in the Vascular Lab Heather Gornik, MD, RVT, RPVI Cleveland Clinic Heart and Vascular Institute Heather L. Gornik, MD has the following relationships to disclose: CVR Global
More informationA VENOUS THROMBOEMBOLISM (VTE) TOWN HALL: Answering Your Top Questions on Treatment and Secondary Prevention
A VENOUS THROMBOEMBOLISM (VTE) TOWN HALL: Answering Your Top Questions on Treatment and Secondary Prevention This handout is a supplemental resource to an educational video activity released on Medscape
More informationNon commercial use only. The treatment of venous thromboembolism with new oral anticoagulants. Background
Italian Journal of Medicine 2013; volume 7(s8):29-35 The treatment of venous thromboembolism with new oral anticoagulants Davide Imberti AUSL Piacenza, Italy ABSTRACT Traditional anticoagulants, such as
More informationTrombosi venose superficiali e trombosi venose distali
XXIV Congresso Nazionale SISET Abano 9-12 Novembre 2016 Trombosi venose superficiali e trombosi venose distali Gualtiero Palareti / Benilde Cosmi Università di Bologna Superficial vein thrombosis (SVT):
More informationAnticoagulation Forum: Management of Tiny Clots
Anticoagulation Forum: Management of Tiny Clots Casey O Connell, MD FACP Associate Professor Jane Anne Nohl Division of Hematology Keck School of Medicine USC DISCLOSURES None 4/11/2017 Objectives Define
More informationUpdates in Diagnosis & Management of VTE
Updates in Diagnosis & Management of VTE Financial Disclosures-NONE TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE- SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA,
More informationImplications from the ACCP 2012 Consensus Guidelines for the Management of Thrombosis: a case based approach
Implications from the ACCP 2012 Consensus Guidelines for the Management of Thrombosis: a case based approach Prof. I. Baumgartner Head Clinical and Interventional Angiology About the ACCP guidelines Widely
More informationWarfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin
1 2:15 pm The Era of : Selecting the Best Approach to Treatment SPEAKER Gregory Piazza, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Gregory Piazza,
More informationSuspected Deep Vein Thrombosis (DVT) Pathway for Non Pregnant patients Updated November 2016, with new D-dimer reference range
Suspected Deep Vein Thrombosis (DVT) Pathway for Non Pregnant patients Updated November 2016, with new D-dimer reference range Suspect a DVT? Complete a Two-level DVT Wells score on ICE system (see page
More informationDVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationDisclosures. What is a Specialty Vein Clinic? Prevalence of Venous Disease. Management of Venous Disease: an evidence based approach.
Management of Venous Disease: an evidence based approach Disclosures Ed Boyle, MD Andrew Jones, MD Dr. Ed Boyle and Dr. Andrew Jones disclose Grants/research support: Medtronic, BTG International, Clearflow,
More informationDOACs in CAT. Fellow: Shweta Jain, MD Faculty Discussant: David Garcia, MD
DOACs in CAT Fellow: Shweta Jain, MD Faculty Discussant: David Garcia, MD Case 65 year old post menopausal female Left breast lesion Oct 2015 Biopsy Invasive ductal carcinoma Lumpectomy with SNB- pt1cno
More informationUC SF. Division of General Internal Medicine UNIVERSITY OF CALIFORNIA SAN FRANCISCO, DIVISION OF HOSPITAL MEDICINE
Updates in the Management of Venous Thromboembolism Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical Director, Anticoagulation Clinic Venous Thromboembolism
More informationObjectives. Venous Thromboembolism (VTE) Prophylaxis. Case VTE WHY DO IT? Question: Who Is At Risk?
Objectives Venous Thromboembolism (VTE) Prophylaxis Rishi Garg, MD Department of Medicine Identify patients at risk for VTE Options for VTE prophylaxis Current Recommendations (based on The Seventh ACCP
More informationPREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM International Consensus Statement 2013 Guidelines According to Scientific Evidence Developed under the auspices of the: Cardiovascular Disease Educational
More informationPerioperative Management of the Anticoagulated Patient
Perioperative Management of the Anticoagulated Patient Citywide Resident Perioperative Medical Consultation Conference 5/5/17 Matthew Eisen, MD Director, Anticoagulation Services MetroHealth Medical Center
More informationEXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS
EXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS Samuel Z. Goldhaber, MD Director, VTE Research Group Cardiovascular Division Brigham and Women s Hospital Professor of Medicine Harvard Medical
More informationStatus of anticoagulation therapy in 2016: Is there a need for venous revascularization?
Status of anticoagulation therapy in 2016: Is there a need for venous revascularization? Rupert M. Bauersachs Dept. of Vascular Medicine, Darmstadt Center of Thrombosis Hemostasis, Mainz Status of anticoagulation
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationNew Anticoagulants and Emerging Strategies
New Anticoagulants and Emerging Strategies in the Treatment of Venous Thromboembolism b Stavros V. Konstantinides, MD, PhD, FESC Head, Department of Cardiology, Democritus University of Thrace, Greece
More informationUpdates in Medical Management of Pulmonary Embolism and Deep Vein Thrombosis. By: Justin Youtsey, Elliott Reiff, William Montgomery, Grant Finlan
Updates in Medical Management of Pulmonary Embolism and Deep Vein Thrombosis By: Justin Youtsey, Elliott Reiff, William Montgomery, Grant Finlan Objectives Describe the prevalence of PE and DVT as it relates
More informationPrimary VTE Thromboprophylaxis
Primary VTE Thromboprophylaxis Controversies in Hematology 53 rd Annual Meeting of Thai Society of Hematology Bundarika Suwanawiboon, MD Division of Hematology Department of Medicine Faculty of Medicine
More informationWhat is the impact of Superficial Vein Thrombosis?
What is the impact of Superficial Vein Thrombosis? Athanasios D. Giannoukas MD, MSc(Lond.), PhD(Lond.), FEBVS Professor of Vascular Surgery Faculty of Medicine, University of Thessalia, Greece Chairman,
More informationMedical Patients: A Population at Risk
Case Vignette A 68-year-old woman with obesity was admitted to the Medical Service with COPD and pneumonia and was treated with oral corticosteroids, bronchodilators, and antibiotics. She responded well
More information10/8/2012. Disclosures. Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines. Goals and Objectives. Outline
Disclosures Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines No relevant conflicts of interest related to the topic presented. Cyndy Brocklebank, PharmD, CDE Chronic Disease Management
More informationCanadian Society of Internal Medicine Annual Meeting 2017 Toronto, ON
Canadian Society of Internal Medicine Annual Meeting 2017 Toronto, ON How to Prevent and Manage the Post-Thrombotic Syndrome? Jean-Philippe Galanaud Clinical Thromboembolism & Division of GIM Sunnybrook,
More informationPULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT
PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT OBJECTIVE: To provide a diagnostic algorithm and treatment options for patients with acute pulmonary embolism (PE). BACKGROUND: Venous thromboembolism (VTE)
More informationVTE ACHIEVEMENTS AND CHALLENGES: 2012 AND BEYOND Samuel Z. Goldhaber, MD Director, VTE Research Group Cardiovascular Division Brigham and Women s
VTE ACHIEVEMENTS AND CHALLENGES: 2012 AND BEYOND Samuel Z. Goldhaber, MD Director, VTE Research Group Cardiovascular Division Brigham and Women s Hospital Professor of Medicine Harvard Medical School October
More informationApproach to Thrombosis
Approach to Thrombosis Theera Ruchutrakool, M.D. Division of Hematology Department of Medicine Siriraj Hospital Faculty of Medicine Mahidol University Approach to Thrombosis Thrombosis: thrombus formation
More informationChanging the Ambulatory Training Paradigm: The Design and Implementation of an Outpatient Pulmonology Fellowship Curriculum
Online Data Supplement Changing the Ambulatory Training Paradigm: The Design and Implementation of an Outpatient Pulmonology Fellowship Curriculum Stacey M. Kassutto, C. Jessica Dine, Maryl Kreider, Rupal
More informationUpdates in venous thromboembolism. Cecilia Becattini University of Perugia
Updates in venous thromboembolism Cecilia Becattini University of Perugia News for VTE Diagnosis Treatment the acute phase the agents Pulmonary embolism: diagnosis Vein ultrasonography Meta-analysis 15
More informationObesity, renal failure, HIT: which anticoagulant to use?
Obesity, renal failure, HIT: which anticoagulant to use? Mark Crowther with thanks to Dr David Garcia and others. This Photo by Unknown Author is licensed under CC BY-SA 1 2 Drug choices The DOACs have
More informationNew Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationAcute and long-term treatment of PE. Cecilia Becattini University of Perugia
Acute and long-term treatment of PE Cecilia Becattini University of Perugia Acute and long-term treatment of VTE What is the optimal acute phase treatment for the patient? Intravenous thrombolysis One
More informationDuration of anticoagulation
Duration of anticoagulation P. Fontana Service d angiologie et d hémostase Hôpitaux Universitaires de Genève Pomeriggio formativo in coagulazione, Bellinzona, 19.10.2017 Conflict of interest AstraZeneca,
More informationIliofemoral DVT: Miminizing Post-Thrombotic Syndrome
Iliofemoral DVT: Miminizing Post-Thrombotic Syndrome Catherine K. Chang, MD FACS Vascular Surgery San Diego Southern California Permanente Medical Group Acute Deep Venous Thrombosis Incidence & Outcomes
More informationThrombosis. Tom DeLoughery, MD FACP. Oregon Health and Sciences University
Thrombosis Tom DeLoughery, MD FACP Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen, Alexion What I am Talking About New Anticoagulants
More informationVenous Thromboembolism Prophylaxis: Checked!
Venous Thromboembolism Prophylaxis: Checked! William Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University of Toronto National Lead, VTE Prevention, Safer
More informationThe legally binding text is the original French version. Opinion 15 May 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 15 May 2013 ARIXTRA 2.5 mg/0.5 ml, solution for injection in pre-filled syringe B/2 (CIP: 34009 359 225 4 0) B/7 (CIP:
More informationRisk-Based Evaluation and Management of VTE
12:50-1:50pm Risk-Based Evaluation and Management of VTE SPEAKER Gregory Piazza, MD, MS BRIGHAM AND WOMEN S HOSPITAL Risk-Based Evaluation and Management of VTE Gregory Piazza, MD, MS Assistant Professor
More informationOutpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015 General Principles: There is compelling data in the medical literature to support
More informationVENOUS THROMBOEMBOLISM: DURATION OF TREATMENT
VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT OBJECTIVE: To provide guidance on the recommended duration of anticoagulant therapy for venous thromboembolism (VTE). BACKGROUND: Recurrent episodes of VTE
More informationPrevention and treatment of venous thromboembolic disease
REVIEW Prevention and treatment of venous thromboembolic disease SUSAN McNEILL AND CATHERINE BAGOT Awareness of the risk factors for venous thromboembolic (VTE) disease and timely administration of thromboprophylaxis
More informationHow long to continue anticoagulation after DVT?
How long to continue anticoagulation after DVT? Dr. Nihar Ranjan Pradhan M.S., DNB (Vascular Surgery), FVES(UK) Consultant Vascular Surgeon Apollo Hospital, Jubilee Hills, Hyderabad (Formerly Faculty in
More informationAnticoagulation Update: VTE Guidelines update, DOACs, procedural warfarin interruption, and icentra (whew!)
Anticoagulation Update: VTE Guidelines update, DOACs, procedural warfarin interruption, and icentra (whew!) Clinical Learning Day 2017 Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain
More informationVenous Thrombo-Embolism. John de Vos Consultant Haematologist RSCH
Venous Thrombo-Embolism John de Vos Consultant Haematologist RSCH overview The statistics Pathogenesis Prophylaxis Treatment Agent Duration Incidental VTE Recurrence of VTE IVC filters CVC related thrombosis
More informationVenous thromboembolic diseases: diagnosis, management and thrombophilia testing (2012) NICE guideline CG144
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (2012) NICE guideline CG144 Appendix A: Summary of new evidence from Summary of evidence from previous year Diagnosis Diagnostic
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationTop 5 (or so) Hematology Consults. Tom DeLoughery, MD FACP FAWM. Oregon Health and Sciences University DISCLOSURE
Top 5 (or so) Hematology Consults Tom FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant/Research none 1 What I am Talking About
More informationTreatment Options and How They Work
Treatment Options and How They Work Robin Offord Director of Clinical Pharmacy UCL Hospitals NHS Foundation Trust robin.offord@uclh.nhs.uk Introducing the term anticoagulant... What they do Inhibit the
More informationThis chapter will describe the effectiveness of antithrombotic
Antithrombotic Therapy for Venous Thromboembolic Disease The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Harry R. Büller, MD, Chair; Giancarlo Agnelli, MD; Russel D. Hull, MBBS,
More informationPULMONARY EMBOLISM/VTE CARE PROCESS MODEL
PULMONARY EMBOLISM/VTE CARE PROCESS MODEL IMCP FALL CONFERENCE 2017 Scott Stevens, MD Co-Director, Thrombosis Clinic & Thrombosis Research Group Intermountain Medical Center Professor of Clinical Medicine
More informationDiscussion Leader: Doug Bias, M.D.
In low-risk patients with isolated calf DVT (IDDVT), what is the morbidity risk of treating with repeat ultrasound/observation versus anticoagulation? Discussion Leader: Doug Bias, M.D. Clinical Scenario:
More informationThe Evidence Base for Treating Acute DVT
The Evidence Base for Treating Acute DVT Mr Chung Sim Lim Consultant Vascular Surgeon and Honorary Lecturer Royal Free London NHS Foundation Trust and University College London NIHR UCLH Biomedical Research
More informationManagement of Post-Thrombotic Syndrome
Management of Post-Thrombotic Syndrome Thanainit Chotanaphuti Phramongkutklao College of Medicine Bangkok, Thailand President of CAOS Asia President of Thai Hip & Knee Society President of ASEAN Arthroplasty
More informationDEEP VENOUS THROMBOSIS A PRACTICAL APPROACH TO IMPROVING CLINICAL OUTCOMES
DEEP VENOUS THROMBOSIS A PRACTICAL APPROACH TO IMPROVING CLINICAL OUTCOMES Jose M. Borromeo M.D. Vascular Surgeon Iowa Heart Center Disclosures: AstraZeneca Pharmaceuticals Cook CVRx LeMaitre Vascular,
More informationPrevention and management of venous thromboembolism M. AAPRO
Prevention and management of venous thromboembolism M. AAPRO Thromboprophylaxisof DVT and PE in AmbulatoryCancerPatients Zurich, February 2017 M. AAPRO Based on a lesson in April 2016 by M. DICATO M.D.,
More informationClinical Guideline for Anticoagulation in VTE
Clinical Guideline for Anticoagulation in VTE These clinical guidelines are intended to provide evidence-based recommendations regarding the anticoagulation in patients with DVT and PE. Please note that
More informationFactor Xa Inhibition in the Management of Venous Thromboembolism: Important Safety Information. Important Safety Information (cont d)
Factor Xa Inhibition in the Management of Venous Thromboembolism: The Role of Fondaparinux WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with
More information10 Key Things the Vascular Community Should Know about the DOACs Heather Gornik, MD, RVT, RPVI
10 Key Things the Vascular Community Should Know about the DOACs Heather Gornik, MD, RVT, RPVI Cleveland Clinic Heart and Vascular Institute Heather L. Gornik, MD has the following relationships to disclose:
More informationFatal P.E. Historic 1-2% Current %
Dr. (Prof.) Anil Arora MS (Ortho) DNB (Ortho) Dip SIROT (USA) FAPOA (Korea), FIGOF (Germany), FJOA (Japan) Commonwealth Fellow Joint Replacement (Royal National Orthopaedic Hospital, London, UK) Senior
More informationSupplementary Online Content
Supplementary Online Content Mismetti P, Laporte S, Pellerin O, Ennezat P-V, Couturaud F, Elias A, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone
More informationSlide 1. Slide 2. Slide 3. Outline of This Presentation
Slide 1 Current Approaches to Venous Thromboembolism Prevention in Orthopedic Patients Hujefa Vora, MD Maria Fox, RN June 9, 2017 Slide 2 Slide 3 Outline of This Presentation Pathophysiology of venous
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More informationPrimary VTE Prophylaxis. Ponlapat Rojnuckarin, MD PhD Chulalongkorn University Bangkok, Thailand
Primary VTE Prophylaxis Ponlapat Rojnuckarin, MD PhD Chulalongkorn University Bangkok, Thailand A 70-yr-old female before THA BMI 31 kg/m 2 with varicose vein What do you recommend for VTE prevention?
More informationSimplified approach to investigation of suspected VTE
Simplified approach to investigation of suspected VTE Diagnosis of DVT and PE THSNA 2016, Chicago 15 April 2016 Clive Kearon, McMaster University, Canada Relevant Disclosures Research Support/P.I. Employee
More informationVTE Management in Surgical Patients: Optimizing Prophylaxis Strategies
VTE Management in Surgical Patients: Optimizing Prophylaxis Strategies VTE in Surgical Patients: Recognizing the Patients at Risk Pathogenesis of thrombosis: Virchow s triad and VTE Risk Hypercoagulability
More information